N(2)M(2) (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma

BACKGROUND: Patients with glioblastoma without O(6)-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation are unlikely to benefit from alkylating chemotherapy with temozolomide (TMZ). Trials aiming at replacing TMZ with targeted agents in unselected patient populations have failed to...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Wick, Wolfgang, Dettmer, Susan, Berberich, Anne, Kessler, Tobias, Karapanagiotou-Schenkel, Irini, Wick, Antje, Winkler, Frank, Pfaff, Elke, Brors, Benedikt, Debus, Jürgen, Unterberg, Andreas, Bendszus, Martin, Herold-Mende, Christel, Eisenmenger, Andreas, von Deimling, Andreas, Jones, David T W, Pfister, Stefan M, Sahm, Felix, Platten, Michael
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2019
Pynciau:
Clinical Investigations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6303534/
https://ncbi.nlm.nih.gov/pubmed/30277538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy161
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg